Zobrazeno 1 - 10
of 425
pro vyhledávání: '"Raf Kinase Inhibitor"'
Autor:
Jing-Quan Wang, Qiu-Xu Teng, Zi-Ning Lei, Ning Ji, Qingbin Cui, Han Fu, Lizhu Lin, Dong-Hua Yang, Ying-Fang Fan, Zhe-Sheng Chen
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
Overexpression of ABCG2 remains a major impediment to successful cancer treatment, because ABCG2 functions as an efflux pump of chemotherapeutic agents and causes clinical multidrug resistance (MDR). Therefore, it is important to uncover effective mo
Externí odkaz:
https://doaj.org/article/abb0176b441e4e7b9749e036468a6809
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 2005 May . 102(21), 7748-7753.
Externí odkaz:
https://www.jstor.org/stable/3375606
Autor:
Joshua Abd Alla, Ursula Quitterer
Publikováno v:
Cells, Vol 11, Iss 4, p 654 (2022)
The RAF kinase inhibitor protein, RKIP, is a dual inhibitor of the RAF1 kinase and the G protein-coupled receptor kinase 2, GRK2. By inhibition of the RAF1-MAPK (mitogen-activated protein kinase) pathway, RKIP acts as a beneficial tumour suppressor.
Externí odkaz:
https://doaj.org/article/46322e8c391a41fcbbc906f4f9f798ea
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Silvia Vivarelli, Luca Falzone, Caterina Maria Grillo, Benjamin Bonavida, Claudia Crimi, Ignazio La Mantia, Massimo Libra
Publikováno v:
Cancers; Volume 14; Issue 4; Pages: 922
Lung cancer (LC) represents a global threat, being the tumor with the highest mortality rate. Despite the introduction of novel therapies (e.g., targeted inhibitors, immune-checkpoint inhibitors), relapses are still very frequent. Accordingly, there
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbf2669b5165a142468360dea9b1828f
https://hdl.handle.net/20.500.11769/524000
https://hdl.handle.net/20.500.11769/524000
Autor:
Darlene Dela Cruz, Mark Merchant, Frances Shanahan, Christopher J. Sneeringer, Paul Gibbons, Shiva Malek, Michael Siu, Matthew R. Durk, Weiru Wang, John Moffat, Jianping Yin, Thomas Hunsaker, Liu Wendy, Dennis Leung, Ivana Yen, Charles Eigenbrot, Joachim Rudolph, Christine S Muli, Hank La, Brendan T. Parr, Antonio G. DiPasquale, Malcolm P. Huestis, Alberto Gobbi, Christine Orr
Publikováno v:
Journal of Medicinal Chemistry. 64:3940-3955
Optimization of a series of aryl urea RAF inhibitors led to the identification of type II pan-RAF inhibitor GNE-0749 (7), which features a fluoroquinazolinone hinge-binding motif. By minimizing reliance on common polar hinge contacts, this hinge bind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5caf4fa1983e44c0d9c529885c02901c
https://doi.org/10.1021/acs.jmedchem.0c02085
https://doi.org/10.1021/acs.jmedchem.0c02085
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Abd Alla, Joshua, Quitterer, Ursula
Publikováno v:
Cells, 11 (4)
The RAF kinase inhibitor protein, RKIP, is a dual inhibitor of the RAF1 kinase and the G protein-coupled receptor kinase 2, GRK2. By inhibition of the RAF1-MAPK (mitogen-activated protein kinase) pathway, RKIP acts as a beneficial tumour suppressor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed7a22ed868c86b7c36d66b6d3ca778
https://hdl.handle.net/20.500.11850/533339
https://hdl.handle.net/20.500.11850/533339
Publikováno v:
Chinese Journal of Lung Cancer, Vol 14, Iss 3, Pp 194-198 (2011)
Background and objective Raf kinase inhibitory protein (RKIP) belongs to the phosphatidylethanolamine binding protein (PEBP) family. RKIP is an endogenous inhibitor of the Raf-1-MEK1/2-ERK1/2 signaling pathway, NFkappaB signaling pathway and G protei
Externí odkaz:
https://doaj.org/article/b7037cc0d51e4a6c9d8818a1f9c27556
Publikováno v:
Biomedicines, Vol 7, Iss 1, p 4 (2019)
AZ628 is a hydrophobic Raf-kinase inhibitor (rapidly accelerated fibrosarcoma) currently in clinical trial of various cancer. The physicochemical properties of hydrophobic drugs that affect the drug-particle interactions and cause aggregation of drug
Externí odkaz:
https://doaj.org/article/0338a90d72be4c69b358455a0c14af18